Medapia (Entacapone)

Entacapone reversibly blocks the peripheral enzyme catechol‑O‑methyltransferase (COMT). By inhibiting this enzyme, the drug slows the breakdown of levodopa, allowing more of the active drug to reach the brain and sustain dopaminergic stimulation for a longer period.

The specific dose of Medapia is determined by the prescribing clinician based on the individual patient's levodopa regimen, disease stage, and tolerability. Healthcare professionals adjust the amount to achieve optimal motor control while minimizing side effects.

The safety of entacapone in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and clinicians usually avoid its use unless the potential benefit justifies the potential risk to the fetus or infant.

To request Medapia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike dopamine agonists or MAO‑B inhibitors, entacapone does not directly stimulate dopamine receptors. Instead, it enhances the existing levodopa therapy by preventing its peripheral breakdown, making it a useful adjunct for patients who still experience OFF periods despite optimal levodopa dosing.

Medapia should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Medapia is taken orally, usually with each dose of levodopa/carbidopa. It is swallowed whole with water and should be taken at the same time as the levodopa-containing medication to maximize its COMT‑inhibiting effect.

Serious risks include liver toxicity, severe allergic reactions such as anaphylaxis, and significant reductions in white‑blood‑cell counts (neutropenia). Patients should be monitored regularly for liver enzyme changes and any signs of hypersensitivity or infection.

Medapia is contraindicated in patients with known hypersensitivity to entacapone or any component of the formulation, those taking non‑selective MAO inhibitors, and individuals with severe hepatic impairment. Caution is also advised for patients with renal dysfunction or a history of severe allergic reactions.